AGMBAgomAb Therapeutics NV - ADR

$9.88
$0.45
(4.36%)
Today
Updated: 04:00 PM EDT
Mkt Cap$481.52M
Vol136,105.00
News
all
press releases
AgomAb Therapeutics (NASDAQ:AGMB) Hits New 52-Week Low - Here's What Happened
AgomAb Therapeutics (NASDAQ:AGMB) Hits New 52-Week Low - Time to Sell...
MarketBeat
News Placeholder
More News
News Placeholder
AgomAb Therapeutics NV's Quiet Period To Expire on March 18th (NASDAQ:AGMB)
AgomAb Therapeutics' (NASDAQ:AGMB - Get Free Report) quiet period is set to expire on Wednesday, March 18th. AgomAb Therapeutics had issued 12,500,000 shares in its IPO on February 6th. The total...
MarketBeat
News Placeholder
AgomAb Therapeutics (NASDAQ:AGMB) Raised to Hold at Zacks Research
Zacks Research raised AgomAb Therapeutics to a "hold" rating in a research report on Wednesday...
MarketBeat
News Placeholder
AgomAb Therapeutics (NASDAQ:AGMB) Stock Price Down 4.5% - Here's Why
AgomAb Therapeutics (NASDAQ:AGMB) Shares Down 4.5% - What's Next...
MarketBeat
News Placeholder
AgomAb Therapeutics (NASDAQ:AGMB) Sets New 1-Year High - Still a Buy?
AgomAb Therapeutics (NASDAQ:AGMB) Hits New 52-Week High - Here's What Happened...
MarketBeat
News Placeholder
AgomAb Therapeutics (NASDAQ:AGMB) Now Covered by Leerink Partners
Leerink Partners began coverage on AgomAb Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $36.00 target price on the stock...
MarketBeat
News Placeholder
Morgan Stanley Initiates Coverage on AgomAb Therapeutics (NASDAQ:AGMB)
Morgan Stanley began coverage on shares of AgomAb Therapeutics in a report on Tuesday. They set an "overweight" rating and a $28.00 target price for the company...
MarketBeat
News Placeholder
AgomAb Therapeutics (NASDAQ:AGMB) Coverage Initiated by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. started coverage on shares of AgomAb Therapeutics in a report on Tuesday. They issued an "overweight" rating and a $32.00 target price on the stock...
MarketBeat
<
...
1
>

Advertisement|Remove ads.